Table 2.
Baseline characteristics of studies investigating vaccination after SARS-CoV-2 infection.
| First author | Study design | Country | Observational period | Vaccine type | Time between SARS-CoV-2 infection and vaccination | Patient number | Age, median [IQR] or mean ± SD | Female, N (%) | ICU admission, N (%) |
|---|---|---|---|---|---|---|---|---|---|
| Tsuchida[26] | Prospective cohort | Japan | NA | NA | 196 [110–238] days | 42 | 40 [30–47] | 12 (46) | NA |
| Strain[27] | Prospective cohort | UK | Mar 20201-Apr 2021 | AZD1222, BNT162b2, mRNA-1273 | 1–3-month, 5.4 %; 3–6-month, 15.0 %; 6–9-month, 8.0 %; >9-month, 71.6 % | 812 | −20, 0.4 %; 21–40, 21.9 %; 41–60, 62.3 %; 60-, 15.5 % | 654 (81) | NA |
| Scherlinger[28] | Retrospective cohort | France | Aug-21 | AZD1222, BNT162b2, mRNA-1273, Ad26.COV2.S | 483 [266–506] days | 397 | 44 [37–50] | 327 (86) | 3 (0.8) |
| Ayoubkhani[18] | Retrospective cohort | UK | Apr 2020-Sep 2021 | AZD1222, BNT162b2, mRNA-1273 | 178 [NA] days | 6,729 | 46 ± 14 | NA | NA |
| Peghin[29] | Prospective cohort | Italy | Mar 2020-May 2020 | AZD1222, BNT162b2, mRNA-1273 | 12.4 ± 1.9 months | 132 | 18–40, 25.0 %; 41–60, 48.5 %; 60-, 26.5 % | 94 (71) | 3 (2.3) |
| Wynberg[30] | Prospective cohort | Netherland | May 2020-Jun 2021 | AZD1222, BNT162b2, mRNA-1273, Ad26.COV2.S | 271 [158–387] days | 87 | 54 [35–61] | NA | NA |
NA, not available.